药学学报, 2021, 56(9): 2367-2371
引用本文:
靖钰, 姚慕蓉, 李松, 陈典泽, 张力, 杨勇, 钟勘, 宗山海. ELISA法检测人血清中重组人信号调节蛋白α-抗CD20人鼠嵌合抗体融合蛋白IMM0306的方法学建立和验证[J]. 药学学报, 2021, 56(9): 2367-2371.
JING Yu, YAO Mu-rong, LI Song, CHEN Dian-ze, ZHANG Li, YANG Yong, ZHONG Kan, ZONG Shan-hai. Development and validation of ELISA method for detection of human signal regulatory protein α-anti-CD20 mouse chimeric antibody fusion protein IMM0306 in human serum[J]. Acta Pharmaceutica Sinica, 2021, 56(9): 2367-2371.

ELISA法检测人血清中重组人信号调节蛋白α-抗CD20人鼠嵌合抗体融合蛋白IMM0306的方法学建立和验证
靖钰1, 姚慕蓉1, 李松2, 陈典泽2, 张力2, 杨勇1, 钟勘1, 宗山海1*
1. 苏州海科医药技术有限公司, 江苏 苏州 215000;
2. 宜明昂科生物医药技术 (上海) 有限公司, 上海 201200
摘要:
IMM0306是重组人信号调节蛋白α-抗CD20人鼠嵌合抗体融合蛋白,拟在临床中治疗难治或复发性CD20阳性B细胞非霍奇金淋巴瘤(B-NHL)。本文建立了ELISA法(酶联免疫吸附法)用于评价人血清中IMM0306的药代动力学。该实验获得中国医学科学院肿瘤医院伦理委员会批准(批准号:CTR20192612)。用重组人CD47蛋白包被过夜,5%脱脂奶粉封闭2 h,洗涤板后,按照板位图每孔加入100 μL样本孵育1.5 h,洗涤后加入生物素标记的检测抗体anti-IMM0306-biotin并孵育1 h,随后加入辣根过氧化物酶(HRP)标记的链霉亲和素孵育1 h,显色并检测。捕获试剂的最佳包被浓度为2 μg·mL-1,检测试剂anti-IMM0306-biotin和链霉亲和素-HRP的最佳稀释度分别为1:500和1:5 000。该方法的定量下限为4 ng·mL-1,标准曲线范围是4~100 ng·mL-1。方法的验证结果均满足相应的接受标准,可以用于IMM0306临床药代动力学研究。
关键词:    CD47      抗体融合蛋白      ELISA      药代动力学     
Development and validation of ELISA method for detection of human signal regulatory protein α-anti-CD20 mouse chimeric antibody fusion protein IMM0306 in human serum
JING Yu1, YAO Mu-rong1, LI Song2, CHEN Dian-ze2, ZHANG Li2, YANG Yong1, ZHONG Kan1, ZONG Shan-hai1*
1. HQ Bioscience Co., Ltd., Suzhou 215000, China;
2. ImmuneOnco Biopharma Co., Ltd., Shanghai 201200, China
Abstract:
IMM0306 is a recombinant human signal regulatory protein α-anti-CD20 mouse chimeric antibody fusion protein, intended to treat refractory or recurrent CD20 positive B-cell non-Hodgkin lymphoma (B-NHL) in clinical. In this study, an ELISA method was established to evaluate the pharmacokinetics of IMM0306 in human serum. The experiment was approved by the Ethics Committee of the Cancer Hospital of the Chinese Academy of Medical Sciences (No. CTR20192612). Recombinant human CD47 protein was coated with the plate overnight, blocking the plate with 5% skin milk for 2 h. After washing, 100 μL per well standard and unknown samples were added, and incubated for 1.5 h. After washing, the detection antibody Anti-IMM0306-Biotin was added and incubated for 1 h, and then HRP-labeled streptavidin was added for 1 h, and the color was detected. The optimal concentration of coating reagent was 2 μg·mL-1 by ELISA method, and the optimal dilution of anti-IMM0306-biotin and SA-HRP were 1:500 and 1:5 000, respectively. The lower limit of quantitation was 4 ng·mL-1, and the standard curve range was 4-100 ng·mL-1. The verification results of the method meets the corresponding acceptance criteria, and can be used in IMM0306 clinical pharmacokinetic studies.
Key words:    CD47    antibody fusion protein    ELISA    pharmacokinetics   
收稿日期: 2021-04-21
DOI: 10.16438/j.0513-4870.2021-0591
通讯作者: 宗山海,Tel:13646214676,E-mail:shanhai.zong@hq-biosci.com
Email: shanhai.zong@hq-biosci.com
相关功能
PDF(400KB) Free
打印本文
0
作者相关文章
靖钰  在本刊中的所有文章
姚慕蓉  在本刊中的所有文章
李松  在本刊中的所有文章
陈典泽  在本刊中的所有文章
张力  在本刊中的所有文章
杨勇  在本刊中的所有文章
钟勘  在本刊中的所有文章
宗山海  在本刊中的所有文章

参考文献:
[1] Klein C, Sustmann C, Thomas M, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies[J]. MAbs, 2012, 4:653-663.
[2] Findlay J, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis:a pharmaceutical industry perspective[J]. J Pharm Biomed Anal, 2000, 21:1249-1273.
[3] Trivedi A, Stienen S, Zhu M, et al. Clinical pharmacology and translational aspects of bispecific antibodies[J]. ClinTransl Sci, 2017, 10:147-162.
[4] Harmonised ICH. Bioanalytical method validation M10[S/OL]. Geneva, Switzerland:ICH Harmonised, 2019-02-26[2021-04-20]. https://www.wrib.org/PDFs/ICH_M10_BMV_Draft_Guideline-190227.pdf.
[5] Chinese Pharmacopoeia Commission. Pharmacopeia of the People's Republic of China (中华人民共和国药典)[S]. 2015 Ed. Beijing:China Medical Science Press, 2015:363-368.
[6] European Medicines Agency. Guideline on bioanalytical method validation[S/OL]. Amsterdam:European Medicines Agency, 2011-07-21[2021-04-20]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.
[7] Food and Drug Administration. Bioanalytical method validation guidance for industry[S/OL]. Silver Spring, US:Food and Drug Administration, 2018-05-24[2021-04-20]. https://www.fda.gov/media/70858/download.
[8] Gunasekaran K, Pentony M, Shen M, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects:applications to bispecific molecules and monovalent IgG[J]. J Biol Chem, 2010, 285:19637-19646.
[9] Zenjiro S, Tomoyuki I, Tetsuhiro S, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity[J]. PLoS One, 2013, 8:e57479.
[10] Stevenson L, Amaravadi L, Myler H, et al. 2014 White Paper on recent issues in bioanalysis:a full immersion in bioanalysis (Part 3-LBA and immunogenicity)[J]. Bioanalysis, 2014, 6:3355-3368.
[11] Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease[J]. Br J Haematol, 2015, 123:850-857.
相关文献:
1.马国昌;陈枢青;朱振洪;黄岩山;潘会强;周金宝.酶联免疫吸附试验法研究PEG-rhG-CSF与rHSA-hG-CSF在小鼠体内的药代动力学[J]. 药学学报, 2007,42(2): 197-200